WallStSmart
HSCS

Heart Test Laboratories Inc. Common Stock

NASDAQ: HSCS · HEALTHCARE · MEDICAL DEVICES

$3.39
-3.42% today

Updated 2026-09-11

Market cap
$13.56M
P/E ratio
P/S ratio
3,140.32x
EPS (TTM)
$-3.48
Dividend yield
52W range
$2 – $4
Volume
0.1M

Heart Test Laboratories Inc. Common Stock (HSCS) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2020202120222023202420252026
Operating cash flow$-3.84M$-2.45M$-3.64M$-5.77M$-6.07M$-7.41M$-7.43M
Capital expenditures$11424.00$712.00$1932.00$18308.00$125271.00$30188.00$44452.00
Depreciation
Stock-based comp$135067.00$24675.00$68396.00$248307.00$405025.00$249884.00$1.31M
Free cash flow$-3.85M$-2.45M$-3.65M$-5.79M$-6.20M$-7.44M$-7.47M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Heart Test Laboratories Inc. Common Stock's revenue?

Heart Test Laboratories Inc. Common Stock's trailing twelve-month revenue is $4319.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is HSCS?

In its most recent fiscal year, HSCS ran a gross margin of -2,982.15%, an operating margin of -194,787.38%, and a net margin of -211,666.47%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does HSCS generate?

HSCS produced $-7.47M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HSCS's balance sheet healthy?

HSCS holds $1.66B in cash and equivalents against — in long-term debt, on $225.53M of shareholder equity. That debt is best read against the cash flow the business throws off each year.